After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics’s Contrave. If the FDA follows the recommendation, Contrave could become the first diet drug to win approval in a decade.
Continue reading FDA Panel Backs Orexigen’s Diet Pill
FDA Panel Backs Orexigen’s Diet Pill originally appeared on DailyFinance on Tue, 07 Dec 2010 20:30:00.
Filed Under: Company News, Health Care, Stocks in the News
Trackbacks/Pingbacks